Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· March 29, 2026

Earnings week ahead: NKE, TLRY, SPCE, BYND, NNDM, CAG, and more

View original at seekingalpha.com
Earnings week ahead: NKE, TLRY, SPCE, BYND, NNDM, CAG, and more [Nest of Eggs] LindaJoHeilman As the calendar turns from March to April, a holiday-shortened week still delivers a diverse set of earnings with the potential to offer fresh directional cues…
Opening lines of the source · Seeking Alpha · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Three Mile Island plant cannot hit grid until 2031

    60% confidence
  • Nike faces margin pressure from tariffs of approximately $1.5B annually and inventory actions, but these are temporary with recovery ahead

    60% confidence
  • Tilray upgraded to Hold, noting that while recent results showed revenue growth and narrowing losses, gross margins declined to 26% due to mix pressures. The BrewDog deal is expected to add ~$200M in annual revenue and $6–8M in adjusted EBITDA

    60% confidence
  • Nike has valuation concerns and estimated ~20% downside despite potential relief from lower tariffs, noting continued policy uncertainty

    60% confidence
  • Acuity Brands rated Hold, noting the stock is trading near fair value with ~8% forward return potential

    60% confidence
  • Virgin Galactic Holdings earns a Sell rating due to weakening momentum and profitability relative to industrial peers

    60% confidence
  • Nike maintains Strong Buy rating with $85 price target, implying ~33% upside and 2.6% yield, citing early success of the Win Now turnaround with 43% Q2 EPS beat, 8% wholesale growth, and 20%+ gains in the running category

    60% confidence
  • Nike upgraded from Hold to Buy rating

    60% confidence
  • Acuity Brands rates as Sell citing valuation concerns and negative EPS revisions

    60% confidence
  • Nike has strong liquidity of approximately $8.35B with insider and institutional buying, and renewed partnerships supporting a multi-year recovery

    60% confidence
  • Tilray upgraded to Hold from Strong Sell

    60% confidence
  • Nike's turnaround remains uncertain, warranting a more neutral stance

    60% confidence
  • Nike downgraded to Hold citing declining profitability, elevated multiples, and ongoing weakness in China

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com